13.3 Exercise and Pharmacologic Stress Testing
Key Takeaways
- NM technologists must recognize basic ECG waveforms, ischemia (ST depression/elevation), and serious arrhythmias that require stopping stress and getting help
- Standard 12-lead placement (limb + V1–V6) and clean skin contact are required for diagnostic stress ECG monitoring
- Bruce and modified Bruce treadmill protocols step speed/grade; bicycle ergometry is an alternative when treadmill is unsuitable
- Know absolute/relative contraindications and termination criteria (drop in SBP, serious arrhythmia, severe angina, patient request, target endpoints)
- Pharmacologic agents: adenosine, dipyridamole, regadenoson (vasodilators—caffeine hold; asthma/COPD cautions) and dobutamine (inotrope/chronotrope); know infusion/bolus timing, RP injection windows, side effects, and aminophylline reversal for vasodilators
13.3 Exercise and Pharmacologic Stress Testing
Quick Answer: Exercise (Bruce / modified Bruce / bike) is preferred when the patient can walk and the ECG is interpretable. Vasodilators (adenosine, dipyridamole, regadenoson) create coronary hyperemia when exercise is inadequate; dobutamine raises demand when vasodilators are contraindicated. Know leads, stop criteria, RP injection timing, side effects, and aminophylline reversal. Caffeine ruins vasodilator stress.
Stress testing is a team process. CNMT items still expect you to set up, monitor, inject on time, and recognize danger.
Basic ECG for the Nuclear Technologist
Conduction path: SA node → atria (P) → AV node/His–Purkinje → ventricles (QRS) → repolarization (T). Watch PR (AV conduction), QRS width (bundle branch/ventricular beats), and ST segment (ischemia zone during stress).
| Finding | Concern | Typical action |
|---|---|---|
| ≥1 mm horizontal/downsloping ST depression | Demand ischemia pattern | Notify supervisor; may meet stop criteria |
| ST elevation (non-Q leads) | Severe ischemia/injury | Stop; urgent evaluation |
| VT, VF, complete heart block, symptomatic bradycardia | Life-threatening | Stop; emergency/ACLS response |
| Unstable rapid AF / SVT with hypotension | Unstable arrhythmia | Stop; treat per protocol |
| Frequent polymorphic PVCs / R-on-T | Malignant potential | Alert; often terminate |
You are not the final ECG reader, but you must not ignore alarms, severe pain with ST change, or collapse.
Lead Placement
Standard 12-lead monitoring:
| Leads | Placement teaching |
|---|---|
| Limb leads | RA, LA, RL, LL (torso-modified/Mason–Likar positions common on treadmill) |
| V1 | 4th ICS right sternal border |
| V2 | 4th ICS left sternal border |
| V3 | Midway V2–V4 |
| V4 | 5th ICS midclavicular line |
| V5 | Level with V4, anterior axillary line |
| V6 | Level with V4–5, midaxillary line |
Prep skin (shave/abrade as needed); fix loose electrodes—motion noise mimics arrhythmia. Baseline LBBB, paced rhythm, digoxin effect, or LVH with strain limits ECG ischemia diagnosis (favor imaging endpoints).
Exercise Protocols
Bruce treadmill: 3-minute stages increasing speed and grade (classically starts 1.7 mph / 10%). Goal often ≥85% maximum predicted HR (rough rule 220 − age) unless symptoms force earlier stop. Inject MPI tracer at peak and continue exercise ~1 minute when safe.
Modified Bruce: gentler early stages for deconditioned or limited patients before standard workloads.
Bicycle ergometry: watt-stepped upright or supine bike when gait is limited or bike imaging geometry is preferred. Same HR, BP, and symptom rules apply.
Contraindications and Termination
Absolute contraindications (teaching—follow lab policy): acute MI (early), high-risk unstable angina, uncontrolled symptomatic arrhythmia, severe symptomatic AS, decompensated HF, acute PE/dissection/myocarditis-pericarditis, inability to cooperate safely.
Relative: left main disease, moderate stenotic valve disease, severe rest HTN, electrolyte extremes, HOCM with obstruction, high-grade AV block—clinician call.
| Stop when… | Examples |
|---|---|
| Absolute | Sustained VT; severe angina with ST elevation; drop in SBP >10 mmHg with ischemia signs; cyanosis; near-syncope; cannot monitor |
| Relative | Progressive chest pain, marked ST depression, marked HTN, fatigue/cramp, patient request |
| Goal reached | Target HR/workload without ischemia—complete tracer dwell per protocol |
Patient request to stop is honored for safety; convert to pharmacologic imaging if the study must finish.
Always record baseline BP/HR, stage-by-stage values, peak rate-pressure product when used, total exercise time, reason for stopping, and exact tracer injection clock time relative to peak stress or drug administration.
Pharmacologic Stress
Use when exercise is inadequate, when LBBB/paced rhythm makes exercise MPI artifact-prone (prefer vasodilator), or when ordered.
Vasodilators
| Agent | Delivery / duration | RP injection timing | Side effects | Reversal |
|---|---|---|---|---|
| Adenosine | IV ~140 µg/kg/min for ~4–6 min | During infusion (often ~3 min into 6-min protocol) | Flushing, chest pressure, dyspnea, AV block, ↓BP | Stop infusion; aminophylline if needed |
| Dipyridamole | IV ~0.56 mg/kg over ~4 min | Tracer ~3–5 min after infusion (lab-specific) | Same class; longer lasting | Aminophylline |
| Regadenoson | Fixed 0.4 mg IV bolus + flush | Tracer ~10–20 s after flush | Dyspnea, headache, flushing | Aminophylline if needed |
Vasodilator cautions: active wheezing / severe asthma or bronchospasm, high-grade AV block without pacemaker, profound hypotension, recent dipyridamole, and caffeine/theophylline not held. Uncontrolled bronchospasm is a hard stop; milder reactive-airway history may steer agent choice toward regadenoson under clinician judgment.
Dobutamine
Dobutamine (β-agonist) raises HR and contractility when vasodilators are contraindicated and exercise is impossible.
| Item | Teaching values |
|---|---|
| Infusion | Escalate (e.g., 5→10→20→30→40 µg/kg/min q3 min—lab protocol) |
| Adjunct | Atropine if HR target unmet |
| RP injection | At peak HR / peak dose stage |
| Side effects | Palpitations, BP swings, arrhythmia, chest pain |
| Control | Stop infusion; β-blocker per clinician—not aminophylline |
Putting Timing Together with MPI
- Confirm prep (caffeine, meds, consent, IV).
- Choose exercise vs pharmacologic from order and safety screen.
- Monitor ECG + BP + symptoms continuously.
- Inject tracer at protocol peak (exercise peak, mid-adenosine, post-regadenoson, post-dipyridamole window, or peak dobutamine).
- Recover; reverse drugs if needed; image after the correct delay.
Bottom line: protect the patient first, hit the physiology window second, and document anything that turns a defect into failed stress rather than true ischemia.
During treadmill MPI, which event is an absolute reason to stop exercise immediately rather than pushing to target heart rate?
A patient cannot exercise and has active bronchospasm. Which stress approach is generally preferred over coronary vasodilators for MPI?
Which statement correctly pairs a pharmacologic MPI agent with tracer-injection timing teaching?